key: cord-0772657-blqc478b authors: Tian, Di; Song, Yang; Zhang, Man; Pan, Yang; Ge, Ziruo; Zhang, Yao; Ren, Xingxiang; Wen, Jing; Xu, Yanli; Guo, Hong; Yang, Peng; Chen, Zhihai; Xu, Wenbo title: Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China date: 2022-02-11 journal: J Med Virol DOI: 10.1002/jmv.27636 sha: 18e274a96ab25f3dafc83d10d680be8a1a32fc52 doc_id: 772657 cord_uid: blqc478b As the coronavirus disease 2019 (COVID‐19) pandemic is still ongoing and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants are circulating worldwide, an increasing number of breakthrough infections are being detected despite the good efficacy of COVID‐19 vaccines. Data on 88 COVID‐19 breakthrough cases (breakthrough infections group) and 41 unvaccinated cases (unvaccinated group) from June 1 to August 22, 2021, were extracted from a cloud database established at Beijing Ditan Hospital to evaluate the clinical, immunological, and genomic characteristics of COVID‐19 breakthrough infections. Among these 129 COVID‐19 cases, 33 whole genomes were successfully sequenced, of which 23 were Delta variants, including 15 from the breakthrough infections group. Asymptomatic and mild cases predominated in both groups, but two patients developed severe disease in the unvaccinated group. The median time of viral shedding in the breakthrough infections group was significantly lower than that in the unvaccinated group (p = 0.003). In the breakthrough infections group, the IgG titers showed a significantly increasing trend (p = 0.007), and the CD4 + T lymphocyte count was significantly elevated (p = 0.018). For people infected with the Delta variant in the two groups, no significant difference was observed in either the quantitative reverse‐transcription polymerase chain reaction results or viral shedding time. In conclusion, among vaccinated patients, the cases of COVID‐19 vaccine breakthrough infections were mainly asymptomatic and mild, IgG titers were significantly increased and rose rapidly, and the viral shedding time was shorter. Coronavirus disease 2019 (COVID-19) has now become a significant public health concern worldwide. Globally, as of January 14 In January 2020, we established a cloud database of COVID-19 patients at Beijing Ditan Hospital. In this study, we extracted a total of 129 adult COVID-19 cases from June to August 2021, and the cases were divided into the breakthrough infection group, which was vaccinated with different types of vaccines, and the unvaccinated group. COVID-19 patients were diagnosed based on the 8th version of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Patients, 11 The data of the 129 COVID-19 cases from the two groups were extracted from the cloud database. Medical record reviews of the patients were performed to collect the patients' underlying medical conditions, laboratory test results, and hospital course. In addition, epidemiological data of the patients were collected. The antibody levels of all patients were followed up to the 4th week after diagnosis A total of 20 patients, 10 in each group were followed up to 8 weeks after diagnosis because of longer viral shedding time and hospital stays. Oropharyngeal swabs, nasopharyngeal swabs, or sputum specimens obtained from the patients during their hospital stay were collected for RT-qPCR testing. RT-qPCR was conducted using a commercial SARS-CoV-2 nucleic acid test kit (BioGerm) with fluorescence PCR detection equipment following the manufacturers' instructions. The results are shown as the cycle threshold (Ct) for the ORF1ab and N genes of SARS-CoV-2. Corresponding serum samples were tested for anti-SARS-CoV-2 antibodies using a chemiluminescence immunoassay (CLIA; Bioscience). Selected swab samples of the patients were then sent to the Beijing CDC for further whole-genome sequencing. Viral RNA was extracted using the Kingfisher Flex Purification System (Thermo Fisher), and libraries were prepared using the Nextera XT Library Prep Kit (Illumina). The resulting DNA libraries were sequenced on a MiniSeq platform (Illumina) using a 300-cycle reagent kit. Mapped assemblies were generated using the SARS-CoV-2 genome (accession number NC_045512) as a reference. Variant calling, genome alignment, and sequence illustrations were generated with CLCBio software. Whole-genome sequence alignment was conducted using the Muscle tool in MEGA (v7.0). A neighbor-joining phylogenetic tree was constructed using MEGA (v7.0), and the Kimura 2parameter model with 1000 bootstrap replicates was used. Genomic lineage designation was performed using the "PANGO lineage" typing method (https://cov-lineages.org/). The statistical analyses were performed using SPSS version 25.0 (SPSS IBM Clinical samples from all 129 COVID-19 cases were acquired for further sequencing. Since the viral loads were relatively low in the tested samples, a total of 33 whole-genome sequences had genome coverage of over (Table 3 ). The phylogenetic tree showed that most of the strains did not cluster together within the same lineage, which shows that the strains were from different countries of origin ( Figure 1 ). The indigenous cases (indicated by a yellow arrow) clustered together because they were related cases. Furthermore, the AZ.2 strains were all imported from Greece, and they formed a clade with a high bootstrap value. The numbers of nucleotide mutations (including substitutions, insertions, and deletions) of the Alpha, Beta, Delta, and AY.2 variants ranged from 53 to 66, 50 to 53, 42 to 63, and 67 to 73, respectively. The numbers of amino acid mutations within the spike protein ranged from 11 to 12, 12 to 13, 8 to 15, and 7 to 8, which is suggestive of a high rate of mutation. The median age of the breakthrough infections group was 33 (26, 38) years, and the median age of the unvaccinated group was 30 (23, 43) years, with no significant difference observed between the two T A B L E 1 Countries of variant origin in the two groups infections group was 23.59 ± 3.75 kg/m 2 , and that of the unvaccinated group was 23.46 ± 4.57 kg/m 2 , also with no significant difference between the two groups. There were also no differences in terms of sex, age, underlying diseases, or BMI between the two groups (Table 2) . Moreover, there were no significant differences in the laboratory tests between the two groups. The laboratory values analyzed in- (Table 2) . However, the average neutrophil count and D-dimer level in the unvaccinated group were higher than those in the breakthrough infections group, but they were all within the normal range. The CD4 + T lymphocyte count, CD8 + T lymphocyte count, B lymphocyte count, and NK cell count were all lower in the unvaccinated group. The CD4 + T lymphocyte count was 580 (378.25, 866.75), which was much lower than that of the breakthrough infection group (821.84 ± 364.98 cells/µl), with a significant difference observed between the two groups (p = 0.018) ( Table 2) . The two groups of patients mainly had either asymptomatic or mild cases; there were 64 (73%) asymptomatic patients and 7 (8%) mild patients in the breakthrough infections group and 25 (61%) asymptomatic patients and 5 (12%) mild patients in the unvaccinated group, with no significant differences observed between the two groups (p = 0.179 and p = 0.518). There were 17 and 9 patients with T A B L E 2 General information and basic laboratory test results for the two groups F I G U R E 1 Neighbor-joining phylogenetic tree based on the whole genome sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The strains from the vaccine breakthrough infections are indicated with red font, while the strains from unvaccinated infections are indicated with blue font. The PANGO lineages are marked and colored on the right. The tree was rooted using strain WH04 (EPI_ISL_406801) in accordance with the root of the PANGO tree which was significantly higher than that in the unvaccinated group (p = 0.000) ( Table 5 ). The IgG titers of the two patients in the unvaccinated group with severe disease were negative at admission. (Table 6 ). Among the 33 patients whose samples were successfully sequenced, [12] [13] [14] In this study, we excluded Pediatric patients because they commonly experience milder illness and atypical clinical manifestations and rarely have lymphopenia, 15 IgA responses against the receptor-binding domain of the spike protein. 23 The above findings suggested that in cases where NAbs cannot be detected, IgG antibodies can be detected instead. 19 Therefore it could be speculated that the neutralizing antibody titers have declined to below protective levels in the vaccinees with breakthrough infections. In addition, we also compared the two NAb levels continue to vary over time after vaccination, near or below the lower limit of seropositivity 6 months after the second dose. 20 cination, which lasted for at least 6-8 weeks. 26 The majority of the antibodies produced for a secondary response are IgG, not IgM, which dominates the early primary response; IgG antibodies also have a higher affinity for pathogens due to the process of somatic hypermutation. 27 In addition, a recent study from JAMA indicated that total receptor-binding domain-specific immunoglobulin with breakthrough infections was significantly higher than participants without breakthrough infections but fully vaccinated, with a 322% high increase. 28 Besides, our study revealed that compared to the unvaccinated group, the breakthrough infections group had higher counts of CD4 + T lymphocytes, CD8 + T lymphocytes, B lymphocytes, and NK cells. T cell-mediated adaptive immune responses are essential for viral clearance and long-term antiviral immunity. 29 44 whereas there was no significant difference with viral shedding time between the two groups in our study. Some studies also showed that vaccination is associated with a faster decline in viral load in Delta variant. 41 However, the small number of Delta variant patients in our study might affect the results so further research will be needed. This study has some limitations that should be mentioned. First, the sample size was relatively small. Second, of the patients in the breakthrough infections group, the initial vaccination to the admission times were different, which may lead to statistical bias. Third, full genome sequencing results were not available for most patients, which may be related to the low viral load (high CT value) in some patients who tested negative in the country of origin. Also, the lacking whole-genome sequences also led to a very small sample size of known genotypes (16) within the breakthrough infections group, which resulted in difficulty of analyzing the difference between Delta breakthrough infections and Non-Delta breakthrough infections. Fourth, neutralization tests were not performed in this study, which is the biggest limitation, providing lessons for our further study. In conclusion, our study summarized the features of COVID-19 vaccine-breakthrough cases in Beijing, China, and indicated that existing vaccinations do not confer full protection against SARS-CoV-2 infection, therefore precaution is still needed among vaccinated people. However, the efficacy of vaccines displayed an obvious advantage in reducing severe symptoms, hospitalization, and deaths. To prevent vaccine breakthrough infections, fully vaccinated populations should still practice preventive measures. Furthermore, many recent studies have indicated that a vaccine booster dose could rapidly recall a SARS-CoV-2-specific immune response, leading to a significant rebound in antibody levels, which promotes high effectiveness against circulating variants such as Delta to prevent breakthrough infection. 20, [45] [46] [47] [48] Therefore, universal booster vaccination could be a current strategy to prevent breakthrough infections from COVID-19. COVID-19 cases from the first local outbreak of the SARS-CoV-2 B.1.1.7 variant in China may present more serious clinical features: a prospective A systematic review of vaccine breakthrough infections by SARS-CoV-2 Delta variant Vaccine breakthrough infections with SARS-CoV-2 variants Breakthrough SARS-CoV-2 infections in prison after vaccination SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta Variant B.1.617.2 and implications for immune evasion National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 8 revision) Implications derived from S-protein variants of SARS-CoV-2 from six continents Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections. medRxiv SARS-CoV-2 Breakthrough Infections in Fully Vaccinated Individuals A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19) Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings -Barnstable County, Massachusetts Covid-19 breakthrough infections in vaccinated health care workers Clinical characteristics of imported COVID-19 patients after inoculating inactivated vaccine Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection Antibody responses and clinical outcomes in adults hospitalized with severe coronavirus disease 2019 (COVID-19): a post hoc analysis of LOTUS China trial Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples Memory B cells and plasma cells: the differentiative continuum of humoral immunity Remembrance of things past: long-term B cell memory after infection and vaccination Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine The geography of memory B cell reactivation in vaccine-induced immunity and in autoimmune disease relapses Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses [published correction appears in Nature A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients Furin cleavage site is key to SARS-CoV-2 pathogenesis Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity Lack of vaccination and associated comorbidities predispose to the need for intensive care in individuals infected with the delta variant -A case cohort study from a tertiary care hospital Rapid spread of the SARS-CoV-2 Delta variant in some French regions Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study Analysis of the Delta variant B.1.617.2 COVID-19 Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospect ive, longitudinal, cohort study The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants Covid-19: Moderna plans booster doses to counter variants Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant We thank all physicians who participated in the management of these COVID-19 cases. This study was funded by the Chang Jiang Scholars Program (grant no 2019077). The authors declare no conflict of interest. Additional supporting information may be found in the online version of the article at the publisher's website.